Clinical safety and tolerance of G-CSF treatment have been established in healthy bone marrow donors treated for 3 to 5 days [26], patients with severe chronic neutropenia treated daily or on alternate days for up to 12 years [32], and patients undergoing ischemic stroke treatment involving G-CSF [24]. The gene discussed is CSF3; the disease is ischemic stroke.